Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 14, 2023 07:00 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union

WALTHAM, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today an update on the ongoing review of its marketing authorization application (MAA) for...
December 11, 2023 07:00 ET | Source: Apellis Pharmaceuticals, Inc.

EMPAVELI® (pegcetacoplan) Provided Long-Term Control of PNH in New Data Presented at ASH Annual Meeting

Rapid improvements in key markers of disease were sustained for up to three years across all adults with PNHMajority of patients remained transfusion free over the long termZero cases of meningococcal...
December 06, 2023 16:05 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM Mass., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced that the company approved the grant of equity awards to 4 new employees with a grant...
November 21, 2023 07:00 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals to Host a Fireside Chat at the 6th Annual Evercore ISI HealthCONx Conference

WALTHAM, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced that the company will host a fireside chat at the 6th Annual Evercore ISI HealthCONx...
November 06, 2023 16:05 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company approved the grant of equity awards to 20 new employees with a grant...
November 04, 2023 13:37 ET | Source: Apellis Pharmaceuticals, Inc.

SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 3 Years in Patients with Geographic Atrophy (GA)

SYFOVRE reduced nonsubfoveal GA lesion growth by over 40% (monthly) in Year 3 compared to projected sham in the GALE extension studyWell-demonstrated safety profile consistent with previously reported...
November 01, 2023 07:05 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals Reports Third Quarter 2023 Financial Results

Generated total revenues of $110.4 million in the third quarter, including $75.3 million for SYFOVRE® (pegcetacoplan injection) and $23.9 million for EMPAVELI® (pegcetacoplan) SYFOVRE showed continued...
October 25, 2023 07:00 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals to Host Conference Call on November 1, 2023, to Discuss Third Quarter 2023 Financial Results

WALTHAM, Mass., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its third quarter...
October 20, 2023 08:00 ET | Source: Apellis Pharmaceuticals, Inc.

The Lancet Publishes 24-Month Results from Phase 3 Studies of SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy (GA)

SYFOVRE demonstrated clinically meaningful reductions in GA lesion growth in as few as six doses per yearOnly treatment approved for use beyond 12 months for GA, a chronic disease and leading cause of...
October 17, 2023 07:00 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis to Present Positive Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G at Kidney Week

In as early as 12 weeks: 80% of patients treated with pegcetacoplan showed a reduction in C3c staining by one or more orders of magnitude of intensity from baseline40% of patients showed zero staining...